CN106798916A - A kind of composition for treating HPV infection and its application - Google Patents
A kind of composition for treating HPV infection and its application Download PDFInfo
- Publication number
- CN106798916A CN106798916A CN201611264447.5A CN201611264447A CN106798916A CN 106798916 A CN106798916 A CN 106798916A CN 201611264447 A CN201611264447 A CN 201611264447A CN 106798916 A CN106798916 A CN 106798916A
- Authority
- CN
- China
- Prior art keywords
- parts
- soft tissue
- mussel
- tissue extract
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a kind of protein compositions for treating HPV infection and its application.The protein compositions are made up of mussel soft tissue extract and trypsase, can optionally include other carriers.The protein compositions that the present invention is provided can be used for HPV infection and the relevant disease of HPV infection, such as cervix cancer and genital wart disease, for HPV infection patient provide good effect, onset time it is short, without the solution for relying on, having no toxic side effect, recurrence rate is low.
Description
Technical field
The present invention relates to medical applications or commodity technical field, more particularly, to a kind of albumen for treating HPV infection
Matter composition and its application.
Background technology
HPV (Human papillomavirus, HPV) belongs to the Papillomavirus of Papillomaviridae,
It is spherical nonencapsulated small-sized double-stranded circular DNA virus.Have now been found that it there are more than 200 kinds, classified according to infection site and wrapped
Include epitheliated type (type of such as 1,5,8,14,20,21,25 and 47) and mucous membrane type (such as 6,11,16,18,31,33,35,39,41,
45th, 51,52,56,58,59,68,70 type), according to whether carcinogenic can be high-risk-type and low risk by HPV points.The pathogenic machine of HPV
System is that HPV has the close preferendum of height to skin and mucosal epithelial cells, after infection host skin or mucosal epithelial cells, can be thin
Self-replacation or it is incorporated into host cell DNA in karyon, and synchronously replicates and transcribe with host cell.In virus replication induction
Skin is bred, and makes the thickening companion's hyperacanthosis of epidermis and to a certain degree keratinization of epidermis, is ultimately resulted in epitheliosis and is formed papilloma, also
Referred to as wart.Wart is usually benign, and wherein HPV DNA are free.But the HPV of some types has the energy of inducing cell transformation
Power, its DNA can be incorporated into the chromosome of host epithelial cells, promote the synthesis of cell DNA, make skin particularly mucosal epithelium
Cell is changed into immortalized cells, so as to induce precancerous lesion or malignant tumour.
HPV infection can cause various lesions, and its clinical manifestation is also varied.Pregnant woman and the population infection of hypoimmunity
The state of an illness will be even more serious afterwards.It is common to have following several：It is cervicitis, cervical erosion, cutaneous papilloma, genital wart, sharp wet
Wart, flat wart etc., even result in malignant tumour, such as cancer of the uterus.
Current HPV it is positive mainly beyond control based on, inside control supplemented by.The outer method controlled include drug therapy, cold therapy,
Laser therapy, micro-wave therapeutic, electricity burn treatment and operative treatment etc..Drug therapy is convenient, it is easy to operate, but some medicines are burnt
The possibility of mucous membrane.The immunopotentiators such as injection of interferon, interleukin can be played a role, but its curative effect is remained in academia and striven
View, and most people can produce certain side effect, and related drugs are expensive.
Mussel (Mytilusedulis Linnaeus) is a kind of sea mollusk, belongs to bivalve shellfish, is commonly called as " blue or green
Mouthful " and " mussel ", each coastwise contries of throughout world.Mussel species are various, and only coastal area of china just has kind more than 30, and economic worth is higher
Have kind more than 10, wherein Mytilus galloprovincialis, Perna viridis and Trachyostracous mussel is main breed variety.Enriched Mussel containing protein, fat,
The nutrients such as carbohydrate, calcium, phosphorus, iron, riboflavin, niacin, and with medical value very high.
Trypsase (Trypsin, Parenzyme), EC 3.4.21.4 are the one kind extracted from the pancreas of ox, sheep, pig
Serine protein hydrolase.After the precursor trypsinogen of pancreas manufacture is secreted into small intestine, erepsin activates it, as pancreas egg
White enzyme.Trypsase is endopeptidase, the carboxyl that it can optionally in the lysine and arginine residues of hydrolyzed peptide chain.
Trypsase not only plays digestive ferment, and can also limit decomposition chymotrypsinogen, procarboxypeptidase, phosphatide proenzyme etc. other
The precursor of enzyme, plays activation.
At present, trypsase is mainly used for cell culture, and the present inventor is in Chinese invention patent application number
201610883795.4 propose the protein compositions containing trypsase and mussel soft tissue extract for treating gynaecology
Inflammation, the gynaecological imflammation is mainly by mould, staphylococcus, streptococcus, Escherichia coli, diplococcus, tubercle bacillus, drop
The inflammation that worm and amoeba worm etc. cause.
The content of the invention
Unexpectedly, the inventors discovered that the combination of mussel soft tissue extract and trypsase can be used to treat HPV
Infection.
According to an aspect of the present invention, the present invention relates to include the protein of mussel soft tissue extract and trypsase
Application of the composition in the medicine for HPV infection is prepared.
One or more implementation methods of the invention, the protein compositions can include by weight：Mussel
0.1-20 parts of soft tissue extract, and trypsase 0.2-20 parts.
One or more implementation methods of the invention, based on the weight of composition, mussel soft tissue extract can be with
Such as 0.1 part, 0.15 part, 0.2 part, 0.25 part, 0.3 part, 0.35 part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part,
0.65 part, 0.7 part, 0.75 part, 0.8 part, 0.85 part, 0.9 part, 0.95 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4
Part, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 11 parts, 12 parts, 13
Part, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts etc., and trypsase can be such as 0.2 part, 0.25 part,
0.3 part, 0.35 part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part, 0.65 part, 0.7 part, 0.75 part, 0.8 part, 0.85
Part, 0.9 part, 0.95 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7
Part, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19
Part, 20 parts etc..
One or more implementation methods of the invention, in the protein compositions：Mussel soft tissue extract with
Trypsase can be individually insulated presence or can be mixed.Here, " isolation is present " refers to two kinds of compositions to keep respective
The non-interfering independent packaging of property is present." being mixed " refers to that two kinds of compositions are mixed in a packaging.
One or more implementation methods of the invention, in the protein compositions：Mussel soft tissue extract with
Trypsase can be dry powder.
One or more implementation methods of the invention, in the protein compositions：Mussel soft tissue extract with
Trypsase can be liquid.
One or more implementation methods of the invention, the protein compositions are formulated as the final ph after liquid
It is 2.5-9.0, for example, it is preferable to pH value is 4.5-8.0, or, such as preferable ph is 5.5-7.0.
One or more implementation methods of the invention, the mussel soft tissue extract be with mussel in addition to shell
All components be raw material, by acidic aqueous solution extract and obtain supernatant, wherein protein content be 0.2-15mg/
Ml, pH value 1.0-6.0.Especially, the mussel soft tissue extract can be carried by acidic aqueous solution by raw material of byssus
The supernatant for taking and obtaining.
One or more aspects of the invention, the mussel includes in Mytilus galloprovincialis, Perna viridis, Trachyostracous mussel
Kind, two or three.
One or more implementation methods of the invention, the acidic aqueous solution can be selected from：Acetic acid-acetate buffer
Liquid, acetic acid, citric acid, perchloric acid etc., but not limited to this.
One or more implementation methods of the invention, the protein content of the mussel soft tissue extract can be
Such as 0.2mg/ml, 0.3mg/ml, 0.4mg/ml, 0.5mg/ml, 0.6mg/ml, 0.7mg/ml, 0.8mg/ml, 0.9mg/ml,
1.0mg/ml、1.5mg/ml、2.0mg/ml、2.5mg/ml、3.0mg/ml、3.5mg/ml、4.0mg/ml、4.5mg/ml、
5.0mg/ml、5.5mg/ml、6.0mg/ml、6.5mg/ml、7.0mg/ml、7.5mg/ml、8.0mg/ml、8.5mg/ml、
9.0mg/ml、9.5mg/ml、10.0mg/ml、10.5mg/ml、11.0mg/ml、11.5mg/ml、12.0mg/ml、12.5mg/
Ml, 13.0mg/ml, 13.5mg/ml, 14.0mg/ml, 14.5mg/ml and 15.0mg/ml etc., but not limited to this.
One or more implementation methods of the invention, the trypsase can be conventional purchase from the market.
Alternatively, the trypsase can be by saltouing, it is prepared by the method such as column chromatography.
One or more implementation methods of the invention, the present invention provides a kind of including mussel soft tissue extract and pancreas
The protein compositions of protease are used to treat HPV infection.
Another aspect of the present invention is related to a kind of pharmaceutical composition for treating HPV infection, it is characterised in that the medicine group
Compound is made up of mussel soft tissue extract of the invention and trypsase.
One or more implementation methods of the invention, the treatment can include that palliative treatment and prevention property is controlled
Treat.
One or more implementation methods of the invention, the HPV infection can be low risk HPV infection, or high-risk
Type HPV infection, particularly high-risk HPV infect, such as HPV16,18,31,33,35,39,41,45,51,52,56,58,59,
68th, 70 type.
Another aspect of the present invention is related to a kind of pharmaceutical composition for treating gynaecological imflammation, wherein, described pharmaceutical composition
Mussel soft tissue extract and trypsase can be included.
One or more implementation method of the invention, described pharmaceutical composition can also include other activity into
Point.
One or more implementation method of the invention, described pharmaceutical composition can also include pharmaceutically acceptable
Carrier.
One or more implementation method of the invention, described pharmaceutical composition can be Formulations for systemic administration or it is local to
Medicine, preferably local administration.
One or more implementation method of the invention, described pharmaceutical composition can be tablet.
One or more implementation method of the invention, described pharmaceutical composition can be liquid agent.
One or more implementation method of the invention, described pharmaceutical composition can be foaming agent.
One or more implementation methods of the invention, described pharmaceutical composition can be gel.
One or more implementation methods of the invention, described pharmaceutical composition can be effervescent tablet.
One or more implementation methods of the invention, the carrier can include any and all of solvent, salt,
Decentralized medium, coating material, surfactant, antioxidant, preservative (such as antiseptic, antifungal agent), isotonic agent, absorption
Delayed-action activator, drug stabilizing agent, adhesive, excipient, disintegrant, lubricant, sweetener, flavouring, dyestuff etc. and they in one
Kind, various or whole combinations, this is well-known to those skilled in the art (for example, see Remington's
Pharmaceutical Sciences,18th Ed.Mack Printing Company,1990,pp.1289-1329).Except
Outside the carrier incompatible with active component, it is contemplated that any conventional carrier used in treatment use or pharmaceutical composition.
A further object of the present invention is related to the protein compositions of the invention described above or pharmaceutical composition to feel in treatment HPV
Application in dye, especially high-risk HPV infection.
A further object of the present invention is related to the sterilization that the protein compositions of the invention described above are used as treatment HPV infection to produce
Product.
A further object of the present invention be the invention described above protein compositions be used as HPV infection maintenance and
Health product.
A further object of the present invention be related to it is a kind of treat the method for HPV infection, including give protein combination of the invention
Thing or pharmaceutical composition.
One or more implementation methods of the invention, protein of the invention is given to subject in need
Composition, the protein compositions are including mussel soft tissue extract and trypsase or are made from it.
One or more implementation methods of the invention, the mussel soft tissue extract and trypsase can be mixed
Conjunction is present in composition.
One or more implementation methods of the invention, the mussel soft tissue extract and trypsase can be point
Ge Li not be present in composition.Here, when by mussel soft tissue extract and trypsase combination medicine-feeding, administration can be
Order of administration is administered simultaneously, and preferably can be order of administration.For order of administration, mussel soft tissue can be extracted
Thing and trypsase are administered in any order.For example, can first give mussel soft tissue extract gives trypsase again, with this
Sequence alternate administration continues whole treatment, or can first give trypsase and give mussel soft tissue extract again, suitable with this
Sequence alternating delivery continues whole treatment, or can be administered with different order in every day for the treatment of.
Using trypsase of the invention and the protein compositions of mussel soft tissue extract, HPV viruse can be killed.
In addition, protein compositions of the invention are adsorbed in the inflammation surface of a wound, the quick healing of the cytoskeleton promotion inflammation surface of a wound is formed simultaneously
The normal condition of disease sites cell can be maintained.Simultaneously as the molecule of the protein ingredient contained in mussel soft tissue extract
Amount is big, will not transdermal or percutaneous absorbtion, can lasting stability played a role in disease sites, extend action time, play long-acting controlling
The effect for the treatment of.
The composition for the treatment of HPV infection prepared by the present invention can rapidly remove lesions position epithelial erosion tissue, isolation disease
Pathogenic microorganism, promotes inflammation to eliminate, and wound repairing eliminates peculiar smell, maintains colony balance, and short treating period, cure rate are high, and without any
Toxic and side effect, does not produce dependence.
Specific embodiment
Following examples are illustrated by taking the composition for treating gynaecological imflammation as an example, but not limited to this, and the invention described above is carried
The various products comprising mussel soft tissue extract and trypsase for going out are applied to the present invention.
Embodiment 1：The preparation method of mussel soft tissue extract.
Take mussel to shell, collect soft tissue 300g, be divided into three parts, in every part of table 1 below of addition 100ml contents 0.3%
Acid solution, centrifugation obtains supernatant as mussel soft tissue extract after homogenate 10min.
Protein content and pH value in supernatant are determined, determining the protein quantity uses Coomassie Brilliant Blue.
Table 1
| Example | Acid solution | Protein content | PH value |
| 1 | Citric acid | 2.6mg/ml | 4.5 |
| 2 | Acetic acid | 3.5mg/ml | 3.2 |
| 3 | Perchloric acid | 3.0mg/ml | 1.0 |
Embodiment 2：A kind of protein compositions for treating HPV infection
It is made up of following components with the composition of trypsase comprising mussel soft tissue extract：Mussel soft tissue extract
Dry powder 15mg, trypsase dry powder 20mg, is separately added into after purified water fully dissolves and obtains oral solution.
Collect through HPV DNA typings detection infection high-risk HPV virus (including 16,18,31,33,35,39,45,51
Type etc.) but female patient 30 without clinical symptoms, it is randomly divided into test group and control group.Test group is taken embodiment 2 and is prepared
Composition, first take mussel soft tissue extract oral solution 10ml, take trypsase oral administration solution after the 30min of interval
Agent 10ml, one time a day, and sexual life and bath in a tub are forbidden during medication, and menstrual period pause is continuous to use 2 weeks.Control group is not used appoints
What remedy measures.After the treatment of all patients sheath is used to the sexual life whole process in the check phase.Two groups of patients are before the treatment
Be discontinued 1 month after carry out HPV detections.
Result is shown, is detected using after the present invention 73.3% patient's HPV viruse carrying capacity and be less than 1.00RLU/Co (HC2
Method), and control group only has 13.3%.Patient's HPV viruse carrying capacity of test group averagely have dropped 78.26%, and the HPV of control group
Virus load averagely increases 4.65% on the contrary.Show that composition of the invention has the effect for the treatment of HPV infection.
Embodiment 3：A kind of protein compositions for treating HPV infection
Composition comprising mussel soft tissue extract, trypsase is made up of following components：Mussel soft tissue extract
Dry powder 10mg, trypsase dry powder 15mg, mussel soft tissue extract and trypsase sieve, and amylum pregelatinisatum, crystallite is fine
Dimension element, sodium carboxymethylcellulose mixing, with 5% Hydroxypropyl methylcellulose aqueous solution granulation, 60 DEG C of drying, low by recipe quantity takes
Mix with particle after being well mixed for hydroxypropyl cellulose, superfine silica gel powder, trypsase, mussel soft tissue extract, after packing
It is made granule.
Collect 30 cervical HPV infection patients, the age between 20-50, course of disease 3-21 months.Cervical HPV infection is diagnosed
Standard is：Cervical exfoliated cell is taken, RLU/Co >=1.0 of sample are detected, cervical HPV infection is diagnosed as positive.Drug dosage is
The granule of the treatment HPV infection of the preparation of embodiment 3 is taken, trypsase 10g is first taken daily, taken after the 30min of interval and made a gift of
Shellfish soft tissue extract 10g, once a day.Continuous use is checked after treating 2 weeks.
Criterion of therapeutical effect：Continuous use checks HPV-DNA after 2 weeks, fully recovered during RLU/Co ＜ 1.0；During RLU/Co ＜ 10.0
It is as effective；It is as invalid during RLU/Co ＞ 10.0.
Clinical effectiveness：In 30 patients, fully recover 21, cure rate 70%, effective 4, efficient (containing recovery from illness)
83.33%, invalid 5, inefficiency is 16.67%.
Conclusion：The composition of present invention treatment HPV infection has good therapeutic action to the patient of HPV infection.
Embodiment 4：A kind of protein compositions for treating HPV infection
Composition comprising mussel soft tissue extract, trypsase is made up of following components：Mussel soft tissue extract
Dry powder 8.5mg, trypsase dry powder 10.5mg, add physiological saline fully to dissolve and are made spray.
The state of an illness treats case one：Pacify certain
Clinical diagnosis：Genitals condyloma acuminatum, HPV is positive；
Clinical treatment：Spray external application prepared by Example 4,3 times a day, is sprayed on every time under the 3-5 of affected part, is within 2 weeks one
The course for the treatment of, totally 3 courses for the treatment of.The flat partial exfoliation of wart soma after drug withdrawal, does HPV detections after being discontinued 20 days, be as a result shown as sun and turn out cloudy.
The state of an illness treats case two：Field so-and-so
Clinical diagnosis：Genital herpes, HPV is positive；
Clinical treatment：Spray external application prepared by Example 4,2 times a day, is sprayed on every time under the 3-5 of affected part, is within one month one
The individual course for the treatment of, totally 1 course for the treatment of.Bleb disappears after drug withdrawal, does HPV detections after drug withdrawal after 20 days, as a result shows that sun is turned out cloudy.
Certainly, the present invention can also have other various embodiments, ripe in the case of without departing substantially from spirit of the invention and its essence
Knowing those skilled in the art can make various corresponding changes and deformation, but these corresponding changes and deformation according to the present invention
The protection domain of the claims in the present invention should all be belonged to.
The application advocates the preferential of the Chinese invention patent application number 201610883795.4 that on October 8th, 2016 submits
Power.
Claims (10)
1. the protein compositions comprising mussel soft tissue extract and trypsase are in the medicine for preparing treatment HPV infection
Using.
2. application according to claim 1, it is characterised in that the protein compositions include by weight：Mussel soft tissue
Extract 0.1-20 parts, trypsase 0.2-20 parts, such as based on the weight of composition, mussel soft tissue extract is, for example,
0.1 part, 0.15 part, 0.2 part, 0.25 part, 0.3 part, 0.35 part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part, 0.65
Part, 0.7 part, 0.75 part, 0.8 part, 0.85 part, 0.9 part, 0.95 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts,
4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 11 parts, 12 parts, 13 parts,
14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, and trypsase be, for example, 0.2 part, 0.25 part, 0.3 part, 0.35
Part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part, 0.65 part, 0.7 part, 0.75 part, 0.8 part, 0.85 part, 0.9 part,
0.95 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts,
8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts.
3. according to the application of foregoing any claim, wherein in the protein compositions：Mussel soft tissue extract and pancreas
Protease is individually insulated presence or is mixed；And/or in wherein described protein compositions：Mussel soft tissue extract and pancreas
Protease is dry powder or liquid.
4. according to the application of foregoing any claim, wherein the final ph that the protein compositions are formulated as after liquid is
2.5-9.0, for example, it is preferable to pH value is 4.5-8.0, for example, it is preferable to pH value is 5.5-7.0；And/or wherein described mussel soft tissue
Extract is that, with mussel as raw material, the supernatant for being extracted by acidic aqueous solution and being obtained, wherein protein content are 0.2-
15mg/ml, pH value 1.0-6.0.
5. according to the application of foregoing any claim, wherein the mussel is including in Mytilus galloprovincialis, Perna viridis, Trachyostracous mussel
It is a kind of, two or three, and/or wherein described acidic aqueous solution includes：Acetic acid-sodium acetate buffer solution, acetic acid, citric acid, height
Chloric acid, or the protein content of wherein described mussel soft tissue extract is, for example, 0.2mg/ml, 0.3mg/ml, 0.4mg/
ml、0.5mg/ml、0.6mg/ml、0.7mg/ml、0.8mg/ml、0.9mg/ml、1.0mg/ml、1.5mg/ml、2.0mg/ml、
2.5mg/ml、3.0mg/ml、3.5mg/ml、4.0mg/ml、4.5mg/ml、5.0mg/ml、5.5mg/ml、6.0mg/ml、
6.5mg/ml、7.0mg/ml、7.5mg/ml、8.0mg/ml、8.5mg/ml、9.0mg/ml、9.5mg/ml、10.0mg/ml、
10.5mg/ml、11.0mg/ml、11.5mg/ml、12.0mg/ml、12.5mg/ml、13.0mg/ml、13.5mg/ml、14.0mg/
Ml, 14.5mg/ml and 15.0mg/ml.
6., according to the application of foregoing any claim, wherein described pharmaceutical composition is by the egg according to foregoing any claim
White matter composition is constituted, or is used to control including the protein compositions according to foregoing any claim, and the medicine
Treat HPV infection.
7. application according to claim 6, wherein the treatment includes palliative treatment and prevention property treatment, or the HPV
Infection is high-risk HPV types infection.
8., according to the application of foregoing any claim 6-7, wherein described pharmaceutical composition also includes pharmaceutically acceptable load
Body.
9., according to the application of foregoing any claim 6-8, wherein described pharmaceutical composition is tablet, liquid agent, foaming agent, solidifying
Jelly or effervescent tablet.
10., according to the application of foregoing any claim 6-9, wherein described pharmaceutical composition is Formulations for systemic administration or local administration.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016108837954 | 2016-10-08 | ||
| CN201610883795 | 2016-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106798916A true CN106798916A (en) | 2017-06-06 |
Family
ID=58906791
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611262155.8A Withdrawn CN106692960A (en) | 2016-10-08 | 2016-12-30 | Application of composition in preparing product used for treating circum anal inflammation |
| CN201611264447.5A Withdrawn CN106798916A (en) | 2016-10-08 | 2016-12-30 | A kind of composition for treating HPV infection and its application |
| CN201710133027.1A Withdrawn CN107007825A (en) | 2016-10-08 | 2017-03-08 | A kind of protein compositions for treating gynaecological imflammation and its application |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611262155.8A Withdrawn CN106692960A (en) | 2016-10-08 | 2016-12-30 | Application of composition in preparing product used for treating circum anal inflammation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710133027.1A Withdrawn CN107007825A (en) | 2016-10-08 | 2017-03-08 | A kind of protein compositions for treating gynaecological imflammation and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN106692960A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019011286A1 (en) * | 2017-07-14 | 2019-01-17 | Jiangyin Usun Pharmaceutical Co., Ltd. | Antiviral use of mussel adhesive proteins |
-
2016
- 2016-12-30 CN CN201611262155.8A patent/CN106692960A/en not_active Withdrawn
- 2016-12-30 CN CN201611264447.5A patent/CN106798916A/en not_active Withdrawn
-
2017
- 2017-03-08 CN CN201710133027.1A patent/CN107007825A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019011286A1 (en) * | 2017-07-14 | 2019-01-17 | Jiangyin Usun Pharmaceutical Co., Ltd. | Antiviral use of mussel adhesive proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106692960A (en) | 2017-05-24 |
| CN107007825A (en) | 2017-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108348577B (en) | Mussel mucin product and application thereof in inhibiting skin inflammation | |
| JP6816098B2 (en) | Igai Adhesive Protein Product and Its Use to Suppress Mucosal Inflammation | |
| JP2009535328A5 (en) | ||
| EP0279984B1 (en) | Pharmaceutical use of graminaceous extracts | |
| WO2002072123A1 (en) | Preventives or remedies for tumor or papillomaviral diseases | |
| CN111265650A (en) | Novel traditional Chinese medicine composition and preparation method thereof | |
| CN103157095A (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| TWI414304B (en) | Treatment of wart with a water soluble extract from plant of solanum genus | |
| US7780992B2 (en) | Antiviral medicament | |
| CN100594911C (en) | Medicine composition and use | |
| CN106798916A (en) | A kind of composition for treating HPV infection and its application | |
| CN107184807A (en) | A kind of anti-acne detumescence facemask powder | |
| JP2015528474A (en) | Application of 3-n-butylisoindolinone in the preparation of drugs for the prevention and treatment of cerebral infarction | |
| US11298393B2 (en) | Composition comprising a mixture of an extract and bentonite | |
| CN106822877A (en) | A kind of composition for treating HPV infection and its application | |
| CN106620673A (en) | Hydrogel for treating infant dental ulcer and preparation method of hydrogel | |
| CN106581659A (en) | Application of composition in treatment of skin inflammations | |
| CN106729673A (en) | A kind of composition for the superficial surface of a wound | |
| CN102526013A (en) | Medicament composition and application thereof | |
| CN104510809A (en) | Antiviral new application of radix sanguisorbae or extract thereof | |
| CN109381466A (en) | Promote the therapeutic agent of diabetic wound healing | |
| CN101069680B (en) | Use of 2-hydroxyl-methyl benzenesulfonic acid in preparing medicine | |
| CN101757039B (en) | Bionic enzymolysis products of geckos and application thereof | |
| JPS61501917A (en) | Trichloroacetoxy-3,4,5,6-tetrachlorobenzoic acid and pharmaceutical compositions | |
| CN106620675A (en) | Application of composition in preparation of product for treating oral mucositis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170606 |